Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
An announcement from Purple Biotech ( (PPBT) ) is now available.
On July 10, 2025, Purple Biotech released an updated corporate presentation highlighting their progress in developing innovative cancer therapies. The presentation emphasized the potential of their Phase 2 clinical stage drugs, CM24 and NT219, to address significant unmet medical needs in various cancers. The company is exploring multiple partnership opportunities and has a cash runway extending into mid-2026, positioning them well for future growth and advancement in oncology treatments.
The most recent analyst rating on (PPBT) stock is a Buy with a $33.00 price target. To see the full list of analyst forecasts on Purple Biotech stock, see the PPBT Stock Forecast page.
Spark’s Take on PPBT Stock
According to Spark, TipRanks’ AI Analyst, PPBT is a Underperform.
Purple Biotech’s overall stock score reflects significant financial challenges and unattractive valuation metrics. The absence of revenue and ongoing losses weigh heavily on financial performance. Technical indicators are mixed, with some potential downside risks. The lack of profitability and dividends further contribute to a low valuation score.
To see Spark’s full report on PPBT stock, click here.
More about Purple Biotech
Purple Biotech is a company operating in the biotechnology industry, focusing on developing first-in-class drug candidates for cancer treatment. Their primary products include CM24, a CEACAM1 antibody, and NT219, an IRS1/2 degrader and STAT3 blocker, both of which are in Phase 2 clinical trials. The company is committed to addressing high unmet medical needs in oncology by targeting specific biomarkers and utilizing a tri-specific antibody platform.
Average Trading Volume: 112,352
Technical Sentiment Signal: Sell
Current Market Cap: $7.01M
See more insights into PPBT stock on TipRanks’ Stock Analysis page.